Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabiralizumab + nivolumab + FOLFOX
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**cabiralizumab + nivolumab + FOLFOX** is an investigational combination therapy used primarily in advanced solid tumors and pancreatic cancer in clinical trials. - **Cabiralizumab** is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), blocking macrophage recruitment and function in the tumor microenvironment. - **Nivolumab** is a monoclonal antibody against programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to promote T-cell mediated anti-tumor activity. - **FOLFOX** is a chemotherapeutic regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, targeting rapidly dividing cells and used mainly in colorectal and other gastrointestinal cancers. This combination is designed to both modify the immune microenvironment and directly target cancer cells, and is given intravenously. The combination has been studied in phase I/II trials for advanced cancers, most notably pancreatic cancer.
- Other names
- cabiralizumab + nivolumab + FOLFOX
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cabiralizumab + nivolumab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabiralizumab + nivolumab + FOLFOX.